Compare CMDB & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CMDB | ACRS |
|---|---|---|
| Founded | 2023 | 2012 |
| Country | Monaco | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 342.8M | 314.2M |
| IPO Year | N/A | 2015 |
| Metric | CMDB | ACRS |
|---|---|---|
| Price | $15.94 | $3.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 39.7K | ★ 3.0M |
| Earning Date | 02-12-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $799,159,000.00 | $15,742,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 152.53 | N/A |
| 52 Week Low | $8.46 | $1.05 |
| 52 Week High | $17.57 | $4.89 |
| Indicator | CMDB | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 61.21 | 60.15 |
| Support Level | $14.91 | $3.71 |
| Resistance Level | $15.45 | $4.84 |
| Average True Range (ATR) | 0.43 | 0.41 |
| MACD | 0.06 | 0.12 |
| Stochastic Oscillator | 85.97 | 54.60 |
Costamare Bulkers Holdings Ltd is an international owner and operator of dry bulk vessels providing multinational transportation of dry bulk commodities for a broad range of customers. Its owned fleet consists of 38 vessels, with a total carrying capacity of approximately 3,017,000 dwt. The company's vessels transport a broad range of bulks across the shipping routes around the world. Iron ore, coal and grain constitute the majority of its cargoes.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.